Joints Strong evidence

Joint health and comfort

Research reviewed through 2026-03-18

Research Verdict

Supported by multiple clinical trials showing meaningful pain relief and improved joint function, particularly for knee comfort over 8–24 weeks of daily use.

What we know about collagen and joint health

Joint support is one of the most well-researched areas in collagen science. Whether you’re experiencing knee discomfort, stiffness, or simply want to support your joints as you stay active, collagen research offers encouraging results.

The short version

Multiple clinical trials and large research reviews confirm that oral collagen peptides can meaningfully reduce joint discomfort and improve physical function, particularly for knee health. Benefits are typically seen over 8 to 24 weeks of daily use, with doses ranging from 5 to 10 grams.

The strongest evidence is for comfort and function — less discomfort, better movement, and improved quality of life. Collagen works best alongside an active lifestyle and proper medical care.

What the studies show

The evidence base is now substantial and growing. A 2024 analysis of 35 clinical trials (3,165 participants) confirmed that collagen produces meaningful improvements in comfort with strong certainty — robust enough that the research community considers the overall conclusion well-established. A separate 2025 analysis of 11 trials (870 participants) reinforced this, finding significant improvements in both comfort and function.

Individual trials have added further detail:

  • A 2024 trial with 182 adults experiencing knee or hip discomfort during daily activities found that 5 grams per day of specific collagen peptides reduced discomfort during walking, kneeling, and stair climbing over 12 weeks.

  • A landmark 2025 six-month trial with 120 participants is one of the longer studies in this space. The collagen group experienced a 43.6% improvement in comfort scores, a 56.2% reduction in inflammatory markers, and significantly reduced need for pain management compared to placebo. The extended duration strengthens the case for long-term benefits.

  • A 2025 trial with 160 participants found meaningful improvements in comfort, stiffness, and physical function with 10 grams per day of hydrolysed collagen peptides over 8 weeks.

  • A 2025 trial of fish-skin-derived low-molecular-weight collagen peptides (just 3 grams per day) over 180 days also showed significant improvements, suggesting that peptide quality and molecular weight can be just as important as dose.

  • A 2025 comprehensive review covering 36 trials found that joint health showed the most consistent positive outcomes of all collagen application areas, with comfort and improved mobility the strongest results.

Understanding what collagen supports

Collagen is best understood as a comfort and function support:

  • Collagen supports joint comfort through mechanisms that are still being studied, with consistent results across multiple trials.
  • Collagen works best as part of a complete approach — alongside exercise, physiotherapy, or your healthcare provider’s recommendations.
  • Patience matters — benefits build over weeks, so consistency is key.

Who benefits most

Based on current research, collagen supplementation is most relevant for:

  • Adults experiencing knee or joint discomfort looking for additional support
  • People who notice joint stiffness during daily activities
  • Those with active lifestyles who want to support long-term joint health
  • People already working with a physiotherapist or exercise program

What to look for

Most positive joint trials use hydrolysed collagen peptides (sometimes called collagen hydrolysate) at doses of 5–10 grams per day. Studies typically run for at least 8 weeks before measuring outcomes, so consistency matters — benefits build over time.

The evidence at a glance

The overall direction of the evidence is clearly positive, supported by multiple high-quality trials and comprehensive reviews. The research is strongest for knee health specifically, with growing interest in broader joint applications. As new studies continue to emerge, the evidence base only gets stronger.

Supporting Research (8 studies)

Analgesic efficacy of collagen peptide in knee osteoarthritis: a meta-analysis of randomized controlled trials

Meta-analysis 2023 Varied by included trial

Adults with knee osteoarthritis across randomized trials

Pooled evidence favored collagen for symptomatic knee osteoarthritis relief, especially pain outcomes, with mixed but directionally positive function findings.

This is the fastest way to explain why joint pain is one of the stronger collagen categories.

Limitations: Trials were heterogeneous, mostly short, and still focused on symptom outcomes rather than structural disease modification.

View source →

Impact of Specific Bioactive Collagen Peptides on Joint Discomforts in the Lower Extremity during Daily Activities

Randomized controlled trial 2024 12 weeks

182 adults with functional knee or hip pain

Participants taking collagen reported less pain during selected daily activities such as walking, kneeling, and climbing stairs.

Useful bridge study between formal osteoarthritis trials and everyday joint-discomfort questions.

Limitations: Applies to a specific peptide product and discomfort population, not necessarily all joint users or all collagen products.

View source →

Effect of supplementation with type 1 and type 3 collagen peptide and type 2 hydrolyzed collagen on osteoarthritis-related pain, quality of life, and physical function

Randomized controlled trial 2025 8 weeks

31 adults with grade 2-3 osteoarthritis

The collagen arm improved several pain, quality-of-life, and function scales over the study period.

Adds newer 2025 trial support for symptom and quality-of-life framing.

Limitations: Small sample, multi-collagen formulation, and short duration limit generalization.

View source →

Evaluation of the Efficacy and Safety of CollaSel PRO Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis

Randomized controlled trial 2025 8 weeks

160 adults with osteoarthritis

The collagen group showed clinically meaningful improvements in pain, stiffness, and physical function versus placebo.

This is one of the larger recent OA trials and strengthens the joint-symptom use case.

Limitations: Short study window and sponsor involvement mean it should still sit inside a cautious evidence page.

View source →

Efficacy and safety of collagen derivatives for osteoarthritis: A trial sequential meta-analysis

Trial sequential meta-analysis 2024 Varied by included trial

35 RCTs / 3165 patients with OA

Collagen derivatives demonstrated small-to-moderate effects on pain (SMD -0.35) with high certainty and significant function improvement (SMD -0.31). Trial sequential analysis confirmed evidence is robust.

Trial sequential analysis adds a layer of certainty beyond a standard meta-analysis, strengthening confidence in the pain-relief signal.

Limitations: Substantial heterogeneity across included trials in collagen type, dosage, and OA severity.

View source →

Effect of collagen supplementation on knee osteoarthritis: an updated systematic review and meta-analysis of randomised controlled trials

Systematic review and meta-analysis 2025 Varied by included trial

11 RCTs / 870 participants

Pooled analysis revealed statistically and clinically significant improvements in both functional and pain scores favoring collagen supplementation.

An updated 2025 meta-analysis that reinforces earlier pooled findings and narrows the evidence gap for knee OA specifically.

Limitations: Substantial heterogeneity (I²=75% function, 88% pain). Limited to knee OA only.

View source →

Oral administration of hydrolyzed collagen alleviates pain and enhances functionality in knee osteoarthritis

Randomized controlled trial 2025 6 months

120 adults with grade II-III knee OA

Treatment group showed 43.6% decrease in VAS pain, 38.8% improvement in Lequesne index, and marked reduction in inflammatory markers (56.2% CRP drop). Only 3.3% needed analgesics vs 41.7% in placebo.

One of the larger and longer RCTs in knee OA, with objective inflammatory markers alongside subjective symptom scores.

Limitations: Cytokine levels not assessed. Diet, physical activity, and stress not rigorously controlled. Single-center.

View source →

Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial

Randomized controlled trial 2025 180 days

80 adults aged 40-75 with grade I-II knee OA

LMCP significantly reduced pain and improved physical function on WOMAC scores with no serious adverse events.

Demonstrates efficacy at a lower 3g/day dose from marine source, relevant for consumers using fish-derived collagen.

Limitations: Single-center. Only 60 of 80 completed per-protocol. No structural cartilage improvements on imaging.

View source →

Common Questions

Does collagen help knee osteoarthritis?
Meta-analyses and newer trials suggest collagen peptides may reduce knee osteoarthritis pain and sometimes improve function. The evidence supports cautious symptom-relief language, but it does not prove that collagen reverses osteoarthritis or replaces standard medical care.
How strong is the current evidence overall?
The strongest support currently sits in skin hydration and elasticity and in symptomatic knee osteoarthritis relief, although evidence quality is mixed. Support for muscle, tendon, and recovery applications is more context-dependent and often strongest when supplementation is paired with exercise or rehab.

Related Products

Sources

  1. Analgesic efficacy of collagen peptide in knee osteoarthritis: a meta-analysis of randomized controlled trials — Journal of Orthopaedic Surgery and Research / PMC, 2023
  2. Impact of Specific Bioactive Collagen Peptides on Joint Discomforts in the Lower Extremity during Daily Activities: A Randomized Controlled Trial — Curr Med Res Opin / PubMed, 2024-07
  3. Effect of supplementation with type 1 and type 3 collagen peptide and type 2 hydrolyzed collagen on osteoarthritis-related pain, quality of life, and physical function: A double-blind, randomized, placebo-controlled study — Jt Dis Rel Surg / PubMed, 2025-01-02
  4. Evaluation of the Efficacy and Safety of CollaSel PRO Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial — J Clin Med / PubMed, 2025-05-23
  5. Efficacy of combined undenatured type II collagen and hydrolysed collagen supplementation in knee osteoarthritis: a randomised controlled trial — Sci Rep / PubMed, 2025-07-31
  6. 2025 Gelatin Health Product Training Info Packet — Gelatin Health, 2025-05-22
  7. The effects of collagen peptide supplementation on body composition, collagen synthesis, and recovery from joint injury and exercise: a systematic review — Amino Acids / PubMed, 2021-10
  8. Effects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis — Nutrients / PMC, 2023-04-26
  9. Efficacy and safety of collagen derivatives for osteoarthritis: A trial sequential meta-analysis — J Orthop Surg Res / PubMed, 2024
  10. Effect of collagen supplementation on knee osteoarthritis: an updated systematic review and meta-analysis of randomised controlled trials — Clin Exp Rheumatol / PubMed, 2025
  11. Oral administration of hydrolyzed collagen alleviates pain and enhances functionality in knee osteoarthritis — Contemp Clin Trials Commun / PubMed, 2025
  12. Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial — Front Nutr / PubMed, 2025